SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Taisho Pharmaceutical Holdings Co., Ltd. TAIPY OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • JP • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $14.00. It has a SharesGrow Score of 70/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Financials: revenue is $301.4B, +1.7%/yr average growth. Net income is $19.0B, growing at +3.1%/yr. Net profit margin is 6.3% (thin). Gross margin is 59% (-3.5 pp trend).

Balance sheet: total debt is $2.6B against $786.6B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 5.09 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $941.5B.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 45/100 (Partial), Past 100/100 (Pass), Health 100/100 (Pass), Moat 79/100 (Pass), Future ?/100 (Fail), Income 45/100 (Partial).

TAIPY SharesGrow Score Overview

74/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 45/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 79/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 45/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TAIPY

No analyst coverage available for this stock.

TAIPY: +1.7%/yr revenue is, +3.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

TAIPY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet TAIPY: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 5.09 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

TAIPY: Gross margin is 59% (-3.5 pp trend), $18B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 79/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

TAIPY: Net profit margin is 6.3%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range8.88-15.5199

Volume275

Avg Volume (30D)202

Market Cap$18.13B

Beta (1Y)0.44

Share Statistics

EPS (TTM)1,583,080,000.00

Shares Outstanding$12.00

IPO Date2021-01-08

Employees8,784

CEOAkira Uehara

Financial Highlights & Ratios

Revenue (TTM)$301.38B

Gross Profit$177.85B

EBITDA$47.67B

Net Income$19B

Operating Income$23.02B

Total Cash$256.17B

Total Debt$2.59B

Net Debt$-255.97B

Total Assets$941.49B

Price / Earnings (P/E)0

Price / Sales (P/S)0.06

Analyst Forecast

Company Info

CountryJP

ExchangeOther OTC

CurrencyUSD

ISINUS87402P1057

Price Chart

TAIPY

Taisho Pharmaceutical Holdings Co., Ltd. ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

8.88 52WK RANGE 15.52

People Also View

Teva Pharmaceutical Industries Limited

Shionogi & Co., Ltd.

Elanco Animal Health Incorporated

Dr. Reddy's Laboratories Limited

HUTCHMED (China) Limited

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message